“Gardasil, One Less Victim of Cervical Cancer?” France says ‘NO’ as they ban Gardasil ads

France says the award winning advertising campaign for Gardasil is false and misleading. The Sanevax Team wants to know - Where was the press coverage when this happened? Why did no one break the news to the public?
 
 
Spread the Word
Listed Under

Tags:
Gardasil
Hpv Vaccine
False Advertising
Cervical Cancer
Merck
France

Industrys:
Health
Media
Government

Location:
Troy - Montana - US

Jan. 4, 2011 - PRLog -- Amidst all of the media hype surrounding HPV vaccines, the traditional press has remained silent on many critical issues, not the least of which occurred on the 31 of August 2010 in France. As of that date, Merck’s marketing partner for the HPV vaccine Gardasil, Sanofli-Pasteur, was officially prohibited from advertising Gardasil for cervical cancer prevention in France.

According to public documentation, the Director General of the French Agency for Safety of Health Products (AFSSAPS) found the sponsor of several Gardasil ads to be in direct violation of the French public health code.

These violations included, but were not limited to:

* Claiming longer efficacy than was actually proven: The ads stated an 8.5 year efficacy period when, in fact, “the only data of validated efficacy of GARDASIL in the WMA is limited to a maximum assessment of the effectiveness of 4.5 years…..”

* Making false claims: The ads in question replaced the officially approved use of Gardasil for the “prevention of low-grade lesions (cervical dysplasia and vulvar)” with statements indicating Gardasil be used for “the prevention of premalignant genital lesions (cervical uterus, vulva and vagina), cancers of the cervix and external genital warts…..”

*More false claims: According to the French Committee on Immunization Practices (CTV) and the High Council of Public Health (HCSP), “the vaccine’s impact on the incidence and mortality of cervical cancer will only become apparent in the long term, in fifteen to twenty-five years….”

With these and other violations in mind, the Director of AFSSAPS stepped up to the plate and prohibited Sanofli-Pasteur from advertising Gardasil as a vaccine to prevent cervical cancer in France.

The SaneVax Team would like to formally thank the French government for examining the situation and taking appropriate action. We sincerely hope governments around the world follow your example and prohibit pharmaceutical companies from continuing to mislead medical professionals and consumers by distorting data and making claims of facts where none exist.

The SaneVax Team would also like to know why this story was not covered by any of our traditional press counterparts. Where are all of the investigative journalists in the world? One has to wonder.

(Note:  Traditional media has ignored this story to such an extent; it took the SaneVax Team some time to confirm the rumor. We had to resort to contacting colleagues working with the Association for those Affected by HPV Vaccines, in Spain to track down official records of the incident. On behalf of medical consumers the world over, SANE Vax, Inc. thanks them for their assistance.)

Sources:

For more info, visit http://www.legifrance.gouv.fr/affichTexte.do;jsessionid=?... to see the French documentation

For more info on AAVP, visit http://www.aavp.es/

# # #

SaneVax believes only Safe, Affordable, Necessary & Effective vaccines and vaccination practices should be offered to the public. Our primary goal is to provide scientific information/resources for those concerned about vaccine safety, efficacy and need.
End
Source:Norma Erickson, President of SaneVax Inc.
Email:***@gmail.com Email Verified
Phone:(406) 295-5218
Zip:59935
Tags:Gardasil, Hpv Vaccine, False Advertising, Cervical Cancer, Merck, Sanofli-pasteur, France
Industry:Health, Media, Government
Location:Troy - Montana - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SaneVax, Inc. PRs
Trending News
Top Daily News
Top Weekly News



Like PRLog?
9K2K1K
Click to Share